Sesen Bio (FRA:PCBK) Days Payable : 0.00 (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Sesen Bio Days Payable?

Sesen Bio's average Accounts Payable for the three months ended in Dec. 2022 was €0.84 Mil. Sesen Bio's Cost of Goods Sold for the three months ended in Dec. 2022 was €0.00 Mil.

The historical rank and industry rank for Sesen Bio's Days Payable or its related term are showing as below:

FRA:PCBK's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Sesen Bio's Days Payable stayed the same from Dec. 2021 (0.00) to Dec. 2022 (0.00). stayed the same

Sesen Bio Days Payable Historical Data

The historical data trend for Sesen Bio's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio Days Payable Chart

Sesen Bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

Sesen Bio Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sesen Bio's Days Payable

For the Biotechnology subindustry, Sesen Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sesen Bio's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sesen Bio's Days Payable distribution charts can be found below:

* The bar in red indicates where Sesen Bio's Days Payable falls into.

Sesen Bio Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Sesen Bio's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (2.525	+	1.164)	/	2 )	/	0	*	365
=	1.8445					/	0	*	365
=	N/A

Sesen Bio's Days Payable for the quarter that ended in Dec. 2022 is calculated as:

	Days Payable (Q: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2022 )	+	Accounts Payable (Q: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2022 )	*	Days in Period
=	( (0.519	+	1.164)	/	2 )	/	0	*	365 / 4
=	0.8415					/	0	*	365 / 4
=	N/A

Sesen Bio Days Payable Related Terms

Thank you for viewing the detailed overview of Sesen Bio's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Sesen Bio (FRA:PCBK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (FRA:PCBK) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.sesenbio.com

Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Sesen Bio (FRA:PCBK) Headlines

From GuruFocus

Pacific Continental Corp. (PCBK) President/COO Roger S Busse buys 1,000 Shares

By GuruFocus Research GuruFocus Editor • 10-15-2009

Pacific Continental Corp. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-04-2009

Pacific Continental Corp. (PCBK) CFO Michael Reynolds sells 1,650 Shares

By GuruFocus Research GuruFocus Editor • 02-22-2010

Pacific Continental Corp. (PCBK) CEO Hal Brown buys 5,000 Shares

By GuruFocus Research GuruFocus Editor • 10-15-2009